TopoTarget (Nasdaq Copenhagen: TOPO) was a Copenhagen-based biotechnology company focused on the discovery and development of drugs and therapies to treat cancer. In 2014, it merged with BioAlliance Pharma and is now part of Onxeo. It was founded in 2000 by a group of clinicians. TopoTarget was involved in collaborations with both academia and industry. In 2001 they began collaborating with the National Cancer Institute, a component of the US National Institutes of Health. Since their acquisition of Prolifix, they have been collaborating with the Netherlands Cancer Institute. They also collaborate with Rigshospitalet, the national hospital of Denmark. TopoTarget has also collaborated with other companies, including Novartis since 2003, and Lundbeck as of October 2007; Topotarget has been member of the Danish Innovation Network Biopeople since 2005. More information...
According to PR-model, topotarget.com is ranked 1,772,260th in multilingual Wikipedia, in particular this website is ranked 984,004th in English Wikipedia.
The website is placed before collectif-artbrut.blogspot.fr and after thejewishmusicreview.com in the BestRef global ranking of the most important sources of Wikipedia.
